Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis

The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.